Atlas Trials

Study of Vadastuximab Talirine (SGN-CD33A; 33A) in Combination With Azacitidine in Patients With Previously Untreated Higher Risk MDS

Clinical trial NCT02706899 · TERMINATED

Trial details

NCT number
NCT02706899
Sponsor
Seagen Inc.
Status
TERMINATED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Myelodysplastic Syndrome
Start date
2016-02-01
Primary completion
2017-11-06
Enrollment
19

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.